ArticleBMC cardiovascular disorders2026
Explainable machine learning and unsupervised anatomical phenotyping of mitral valve prolapse in patients with severe mitral regurgitation.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitral annular disjunction (MAD) is increasingly recognized in mitral valve prolapse (MVP), but its anatomical embedding within degenerative MVP remains incompletely defined. We assessed whether explainable supervised learning and unsupervised clustering could identify MAD-associated MVP phenotypes.
methodsWe analyzed a public surgical cohort of 979 patients with MVP and clinically significant mitral regurgitation. Etiology was classified as Barlow disease (BD) or fibroelastic deficiency (FED). Logistic regression, Random Forest and XGBoost were evaluated for MAD prediction using nested cross-validation with threshold optimization, and assessed for discrimination, calibration and net benefit (decision-curve analysis). XGBoost explainability was assessed using SHAP. UMAP-based clustering using anatomical and clinical variables (excluding MAD and etiology from the input) was performed, with prespecified cluster-number and stability sensitivity analyses.
resultsUnsupervised phenotyping identified three anatomical clusters. The smallest cluster (n = 91, 9.3%) showed the highest MAD prevalence (36.3% vs. 12.0% and 15.8%), marked BD enrichment (95.6%), universal bileaflet prolapse and ≥ 4-scallop involvement, larger MV diameters and less chordal rupture; this phenotype was reproducible across UMAP settings. Supervised models showed only moderate MAD discrimination (XGBoost AUROC 0.695 ± 0.057; PR-AUC 0.314 ± 0.066), with modest calibration (Brier 0.13-0.20; slopes < 1) and limited net benefit, and were therefore interpreted as explanatory rather than diagnostic. SHAP identified BD status as the strongest contributor, followed by number of prolapsing scallops, mitral valve diameters, LV volumes and bileaflet prolapse.
conclusionExplainable and unsupervised analyses concordantly identified a MAD-enriched, BD-dominant bileaflet/multiscallop MVP phenotype, supporting the concept that MAD is embedded within broader annular-leaflet remodeling rather than being an isolated binary abnormality. These findings require prospective, multimodality, outcome-linked external validation before clinical application.
Indexed as
Identifiers
42881371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.